Sonazoid is named as an intervention in 2 current clinical trials in our Netherlands and Switzerland registers. 2 are recruiting patients now. The most common phase is Phase 2/3. The sponsor with the most trials is The Netherlands Cancer Institute (1). The most-studied condition is Melanoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
NCT05470205 · ClinicalTrials.gov ↗ · Liver Diseases, Portal Hypertension
|
Phase 3 | Recruiting | Thomas Jefferson University | Switzerland |
|
Contrast-enhanced Ultrasound for Sentinel Node Detection
NCT07310758 · ClinicalTrials.gov ↗ · Melanoma, Breast Cancer, Head & Neck Cancer
|
Phase 2/3 | Recruiting | The Netherlands Cancer Institute | Netherlands |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| The Netherlands Cancer Institute | 1 |
| Thomas Jefferson University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Netherlands | 1 | 1 |
| Clinical trials in Switzerland | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Netherlands and Switzerland registers name Sonazoid as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in Netherlands and 1 with sites in Switzerland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The Netherlands Cancer Institute (1) and Thomas Jefferson University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Sonazoid works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sonazoid works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sonazoid (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.